Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Hormonal
  • BRCA1 Protein
  • Breast Neoplasms
  • Neoplasm Proteins
  • Tamoxifen
  • Transcription Factors

abstract

  • Tamoxifen use reduces the risk of contralateral breast cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene. The protective effect of tamoxifen seems independent of that of oophorectomy.

publication date

  • December 2, 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11130383

Additional Document Info

start page

  • 1876

end page

  • 81

volume

  • 356

number

  • 9245